Vimian Group AB (0V0 – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Adela Dashian from Jefferies maintained a Buy rating on the stock and has a SEK50.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Adela Dashian’s rating is based on Vimian Group AB’s strategic acquisition of AllAccem Inc., a company specializing in veterinary dental care. This acquisition is expected to enhance Vimian’s MedTech portfolio by adding a high-growth, high-margin business that complements its existing operations.
The acquisition of AllAccem, known for its leading product SANOS, offers Vimian a strong position in the veterinary dental consumables market. Although the immediate financial impact is minimal, the long-term potential for expansion, particularly through Vimian’s global infrastructure, supports the Buy rating. The transaction is strategically aligned with Vimian’s goals and is set to be completed using existing cash reserves.
According to TipRanks, Dashian is a 4-star analyst with an average return of 12.6% and a 63.24% success rate. Dashian covers the Consumer Cyclical sector, focusing on stocks such as Thule Group AB, MIPS AB, and Tomra Systems ASA.